Trial · NCT01271933
Results by group531
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 531
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Double-Blind Phase: Time to Loss of Therapeutic Response (LTR) | Pregabalin (Double Blind Phase) | 58 | 95% Confidence Interval 45 to NA | Days | |
| Double-Blind Phase: Time to Loss of Therapeutic Response (LTR) | Placebo (Double Blind Phase) | 23 | 95% Confidence Interval 14 to 41 | Days | |
| Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event | Pregabalin (Double Blind Phase) | 34 | Participants | ||
| Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event | Placebo (Double Blind Phase) | 41 | Participants | ||
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 1 | -0.9 | Standard Deviation 1.17 | Units on a scale |
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 2 | -1.5 | Standard Deviation 1.51 | Units on a scale |
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 3 | -2.0 | Standard Deviation 1.85 | Units on a scale |
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 4 | -2.3 | Standard Deviation 2.01 | Units on a scale |
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 5 | -2.5 | Standard Deviation 2.00 | Units on a scale |
| Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6 | Pregabalin (Single Blind Phase) | Week 6 | -2.6 | Standard Deviation 2.13 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Pregabalin (Double Blind Phase) | Week 7 | -3.9 | Standard Deviation 1.49 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Placebo (Double Blind Phase) | Week 7 | -3.0 | Standard Deviation 1.59 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Pregabalin (Double Blind Phase) | Week 8 | -3.7 | Standard Deviation 1.72 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Placebo (Double Blind Phase) | Week 8 | -2.7 | Standard Deviation 1.99 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Pregabalin (Double Blind Phase) | Week 9 | -3.6 | Standard Deviation 2.01 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Placebo (Double Blind Phase) | Week 9 | -2.8 | Standard Deviation 1.91 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Pregabalin (Double Blind Phase) | Week 10 | -3.7 | Standard Deviation 1.96 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Placebo (Double Blind Phase) | Week 10 | -2.4 | Standard Deviation 2.01 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Pregabalin (Double Blind Phase) | Week 11 | -3.7 | Standard Deviation 2.21 | Units on a scale |
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 | Placebo (Double Blind Phase) | Week 11 | -2.6 | Standard Deviation 1.94 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01271933/results